Abstract
The increasing global life expectancy brings forth challenges associated with age-related cognitive and motor declines. To better understand underlying mechanisms, we investigated the connection between markers of biological brain aging based on magnetic resonance imaging (MRI), cognitive and motor performance, as well as modifiable vascular risk factors, using a large-scale neuroimaging analysis in 40,579 individuals of the population-based UK Biobank and Hamburg City Health Study. Employing partial least squares correlation analysis (PLS), we investigated multivariate associative effects between three imaging markers of biological brain aging – relative brain age, white matter hyperintensities of presumed vascular origin, and peak-width of skeletonized mean diffusivity – and multi-domain cognitive test performances and motor test results. The PLS identified a latent dimension linking higher markers of biological brain aging to poorer cognitive and motor performances, accounting for 94.7% of shared variance. Furthermore, a mediation analysis revealed that biological brain aging mediated the relationship of vascular risk factors — including hypertension, glucose, obesity, and smoking — to cognitive and motor function. These results were replicable in both cohorts. By integrating multi-domain data with a comprehensive methodological approach, our study contributes evidence of a direct association between vascular health, biological brain aging, and functional cognitive as well as motor performance, emphasizing the need for early and targeted preventive strategies to maintain cognitive and motor independence in aging populations.
Competing Interest Statement
JG has received speaker fees from Lundbeck, Janssen-Cilag, Lilly, Otsuka and Boehringer outside the submitted work. JF reported receiving personal fees from Acandis, Cerenovus, Microvention, Medtronic, Phenox, and Penumbra; receiving grants from Stryker and Route 92; being managing director of eppdata; and owning shares in Tegus and Vastrax; all outside the submitted work. GT has received fees as consultant or lecturer from Acandis, Alexion, Amarin, Bayer, Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daichi Sankyo, Portola, and Stryker outside the submitted work. The remaining authors declare no conflicts of interest.
Funding Statement
This work was supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG): Schwerpunktprogramm (SPP) 2041 (S.E., G.T.), project number 454012190 as well as Sonderforschungsbereich (SFB) 936, project number 178316478, Project C2 (J.F., G.T., and B.C.) & C7 (S.K., J.G.). Furthermore, SBE acknowledges funding by the European Unions Horizon 2020 Research and Innovation Program (grant agreements 945539 (HBP SGA3) and 826421 (VBC)), the Deutsche Forschungsgemeinschaft (DFG, SFB 1451 & IRTG 2150) and the National Institute of Health (R01 MH074457).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UKBs ethical approval was granted by the North West Multi-Centre Research Ethics Committee (MREC). Details on the Ethics and Governance framework are provided online (https://www.ukbiobank.ac.uk/media/0xsbmfmw/egf.pdf) [18]. The HCHS was approved by the local ethics committee of the Landesaerztekammer Hamburg (State of Hamburg Chamber of Medical Practitioners, PV5131). Written informed consent was obtained from all participants. Data acquisition procedures followed the Good Clinical Practice (GCP) and Good Epidemiological Practice (GEP) guidelines according to the Declaration of Helsinki [19].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
